{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:32:23Z","timestamp":1777581143323,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurophysiology"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.clinph.2008.08.007","type":"journal-article","created":{"date-parts":[[2008,10,2]],"date-time":"2008-10-02T05:31:59Z","timestamp":1222925519000},"page":"2507-2512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"title":["Immune-mediated neuropathies in myeloma patients treated with bortezomib"],"prefix":"10.1016","volume":"119","author":[{"given":"Sabrina","family":"Ravaglia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Corso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Piccolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Lozza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Alfonsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Mangiacavalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzia","family":"Varettoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Zappasodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arrigo","family":"Moglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Lazzarino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clinph.2008.08.007_bib1","first-page":"741","article-title":"Psychometric evaluation of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group-Neurotoxicity (Fact\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy","volume":"13","author":"Calhoun","year":"2003","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.clinph.2008.08.007_bib2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.expneurol.2006.11.010","article-title":"Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat","volume":"204","author":"Cavaletti","year":"2007","journal-title":"Exp Neurol"},{"issue":"8","key":"10.1016\/j.clinph.2008.08.007_bib3","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1212\/WNL.53.8.1660","article-title":"Total neuropathy score: validation and reliability study","volume":"53","author":"Cornblath","year":"1999","journal-title":"Neurology"},{"issue":"Suppl.","key":"10.1016\/j.clinph.2008.08.007_bib4","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1002\/ana.410270706","article-title":"Electrophysiology in Guillain\u2013Barre syndrome","volume":"27","author":"Cornblath","year":"1990","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.clinph.2008.08.007_bib5","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induced apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinph.2008.08.007_bib6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of Bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinph.2008.08.007_bib7","first-page":"786","article-title":"Bortezomib therapy alone and in combination with dexamethasone for patients with previously untreated multiple myeloma","volume":"106","author":"Jagannath","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"2","key":"10.1016\/j.clinph.2008.08.007_bib8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00280-006-0259-9","article-title":"A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies","volume":"59","author":"Ma","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.clinph.2008.08.007_bib9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1615\/CritRevImmunol.v26.i6.20","article-title":"The proteasome and its inhibitors in immune regulation and immune disorders","volume":"26","author":"Nencioni","year":"2006","journal-title":"Crit Rev Immunol"},{"issue":"4","key":"10.1016\/j.clinph.2008.08.007_bib10","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1085-9489.2005.00052.x","article-title":"Chronic inflammatory demyelinating polyneuropathy after autologous peripheral blood stem cell transplantation","volume":"10","author":"Peters","year":"2005","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.clinph.2008.08.007_bib11","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of Bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clinph.2008.08.007_bib12","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinph.2008.08.007_bib13","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clinph.2008.08.007_bib14","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1212\/01.WNL.0000158681.29117.8B","article-title":"Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers","volume":"64","author":"Richez","year":"2005","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.clinph.2008.08.007_bib15","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/art.21814","article-title":"Guillain-Barr\u00e9 and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy","volume":"54","author":"Shin","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.clinph.2008.08.007_bib16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.clon.2005.12.008","article-title":"An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib","volume":"18","author":"Stubblefield","year":"2006","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"3","key":"10.1016\/j.clinph.2008.08.007_bib17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/mus.20924","article-title":"Tumor necrosis factor-alpha antagonists and neuropathy","volume":"37","author":"Stubgen","year":"2008","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.clinph.2008.08.007_bib18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1529-8027.2007.00134.x","article-title":"Guillain-Barr\u00e9 syndrome after combined CHOP and rituximab therapy in non-Hodgkin lymphoma","volume":"12","author":"Terenghi","year":"2007","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.clinph.2008.08.007_bib19","series-title":"The CSF proteins: A biochemical approach","author":"Thompson","year":"1988"},{"issue":"5","key":"10.1016\/j.clinph.2008.08.007_bib20","first-page":"5","article-title":"Bortezomib-combination based therapy in relapsed-refractory myeloma patients","volume":"2","author":"Zappasodi","year":"2006","journal-title":"Haematologica"}],"container-title":["Clinical Neurophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1388245708009231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1388245708009231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T10:43:54Z","timestamp":1761389034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1388245708009231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S1388245708009231"],"URL":"https:\/\/doi.org\/10.1016\/j.clinph.2008.08.007","relation":{},"ISSN":["1388-2457"],"issn-type":[{"value":"1388-2457","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-mediated neuropathies in myeloma patients treated with bortezomib","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurophysiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinph.2008.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}